Clinical trial · Interventional
Dose Finding Study of KRN125 (Pegfilgrastim) for Treatment of Neutropenic Patients
A Randomized Dose Finding Study of KRN125 (Pegfilgrastim) for the Treatment of Chemotherapy - Induced Neutropenia in Malignant Lymphoma
NCT00364468CI-TRIAL-00026248completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To assess the duration of severe neutropenia in cycle 1 of chemotherapy after treatment with a single injection of KRN125 or multiple daily injections of filgrastim.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neutropenia | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| pegfilgrastim | Drug | Pegfilgrastim | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To compare the duration of severe neutropenia
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 74 Years
Show eligibility criteria text
Inclusion Criteria: * patients diagnosed as malignant lymphoma * patients who were refractory to anthracycline or anthraquinone containing chemotherapy * patients who are going to receive ESHAP or CHASE treatment regimen * ECOG performance status =\< 2 * patients who have appropriate bone marrow, hepatic and renal functions * written informed consent Exclusion Criteria: * double cancer * history of bone marrow transplantation or PBSCT * more than 2 prior chemotherapy regimens * primary hematologic disease such as myelodysplastic syndrome * previous radiotherapy within 4 weeks of enrollment * woman of childbearing potential who were either pregnant, breast feeding * patients who participated in other clinical trials within the last 4 weeks of enrollment
References
Publications (0)
Data not yet available
No reference posted for this study.